A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

Risperidone long-acting injection: a review of its long term safety and efficacy

(2011) Michael Rainer   Neuropsychiatric Disease and Treatment

P03-21 Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine: Randomized, long-term, open-label, clinical trial results (ConstaTRE)

(2009) W. Gaebel et al.   EUROPEAN PSYCHIATRY

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

(2009) Michelle Kramer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia

(2009) John Lauriello et al.   JOURNAL OF CLINICAL PSYCHIATRY

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia

(2009) David Hough et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

(2009) David Hough et al.   SCHIZOPHRENIA RESEARCH

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET

Tactics and technologies to manage nonadherence in patients with schizophrenia

(2008) William M. Glazer et al.   Current Psychiatry Reports